MAZE NASDAQ
Credit Risk of going bust: lower than 59% of companies Debt: 3.3% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.10 (down 99.7%), Maze Therapeutics, Inc. would be worth roughly what it owes.
Total debt $60.4M against a stock market value of $1.76B.
Distance to default 6.15 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $19.5M (short-term plus half of long-term), stock volatility 70.9%; Altman Z'' 5.87. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
South San Francisco, CA 94080
US
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Coloma Jason V | S-Sale | 2,593 | $27.02 | 2026-10-01 |
| Coloma Jason V | S-Sale | 31,908 | $27.02 | 2026-10-01 |
| Bernstein Harold | M-Exempt | 16,141 | $10.42 | 2026-10-01 |
| Bernstein Harold | S-Sale | 16,141 | $26.93 | 2026-10-01 |
| Bernstein Harold | M-Exempt | 16,141 | $10.42 | 2026-10-01 |